# AngioDynamics, Inc. (ANGO) Stock Analysis: Uncovering a 32% Potential Upside with Robust Buy Ratings

- Link: https://www.directorstalkinterviews.com/angiodynamics-inc-ango-stock-analysis-uncovering-a-32-potential-upside-with-robust-buy-ratings/4121259663
- Published: 2026-08-07T10:20:51+01:00
- Author: Madison Wilson

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector 
focusing on medical instruments and supplies, presents an intriguing opportunity
for investors seeking growth in the medical technology arena. With a market capitalization
of $624.53 million, AngioDynamics has established itself as a reliable entity in
the treatment of cardiovascular diseases and cancer diagnoses, both domestically
and internationally.

The company’s stock is currently priced at $15.11, hovering at the higher end of
its 52-week range of $8.45 to $15.19. Despite a modest price change of just $0.07,
the stock’s resilience and performance metrics are worth noting. The technical indicators
reflect a bullish sentiment, with the stock trading above its 50-day and 200-day
moving averages of $13.04 and $11.85, respectively. A high RSI (14) of 80.58 suggests
the stock is currently overbought, reflecting strong buying interest.

AngioDynamics has reported a commendable revenue growth of 8.00%, although its financial
metrics reveal some challenges. The lack of a trailing P/E Ratio and a negative 
Forward P/E of -335.78 highlight ongoing profitability issues. The company’s EPS
stands at -0.88, and a Return on Equity (ROE) of -20.77% indicates that there is
room for significant improvement in financial performance.

Despite these challenges, AngioDynamics has managed to maintain a positive free 
cash flow of $21.77 million, which underscores its operational efficiency and ability
to reinvest in growth opportunities. The company does not currently offer a dividend
yield, which is typical for firms reinvesting earnings to fuel expansion.

Analyst sentiment towards AngioDynamics is notably optimistic, with four buy ratings
and no hold or sell recommendations. Analysts have set a target price range between
$17.00 and $24.00, with an average target of $20.00. This suggests a potential upside
of 32.36% from the current price, making it an attractive proposition for growth-
oriented investors.

AngioDynamics’ innovative product offerings, such as the Auryon Atherectomy system
and the AlphaVac mechanical thrombectomy system, position it well within the competitive
medical technology landscape. The company’s NanoKnife IRE Ablation System and VenaCure
EVLT system further diversify its portfolio, catering to a wide spectrum of medical
needs.

Founded in 1988 and headquartered in Latham, New York, AngioDynamics continues to
expand its footprint in the medical technology market. The company’s focus on innovative
solutions for complex medical conditions ensures its relevance and potential for
sustained growth.

Investors eyeing the healthcare sector should consider AngioDynamics as a promising
candidate for their portfolios. While the company faces fiscal challenges, its robust
product lineup, strategic market positioning, and strong analyst endorsement provide
a compelling case for potential investment gains.

Share on: